Minerva Neurosciences (NERV) Projected to Announce Quarterly Earnings on Wednesday

Minerva Neurosciences (NASDAQ:NERV) is expected to be announcing its Q3 2026 results before the market opens on Wednesday, November 4th. Analysts expect Minerva Neurosciences to post earnings of ($0.14) per share for the quarter. Individuals can check the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Thursday, November 5, 2026 at 12:30 PM ET.

Minerva Neurosciences (NASDAQ:NERV) last announced its quarterly earnings results on Friday, August 7th. The biopharmaceutical company reported ($0.14) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.05. On average, analysts expect Minerva Neurosciences to post ($0.73) EPS for the current fiscal year and ($0.42) EPS for the next fiscal year.

Minerva Neurosciences Stock Down 0.2%

Minerva Neurosciences stock opened at $2.23 on Wednesday. The company has a 50 day moving average of $3.64 and a 200-day moving average of $4.91. Minerva Neurosciences has a twelve month low of $2.12 and a twelve month high of $8.80. The stock has a market capitalization of $106.29 million, a PE ratio of -0.08 and a beta of -0.10.

Analyst Upgrades and Downgrades

NERV has been the topic of several research reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Minerva Neurosciences in a research report on Monday, September 21st. Wall Street Zen raised shares of Minerva Neurosciences from a “sell” rating to a “hold” rating in a research note on Saturday, August 8th. Zacks Research upgraded Minerva Neurosciences from a “strong sell” rating to a “hold” rating in a report on Friday, October 9th. Finally, Jefferies Financial Group upgraded Minerva Neurosciences from a “hold” rating to a “mixed” rating and increased their target price for the stock from $7.50 to $10.00 in a report on Friday, August 14th. One equities research analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $10.33.

About Minerva Neurosciences

Minerva Neurosciences, Inc is a biopharmaceutical company focused on developing treatments for central nervous system disorders. The company’s research has centered on conditions with significant unmet medical needs, including schizophrenia, depression and other psychiatric or neurological diseases.

Minerva’s lead product candidate has been roluperidone, an investigational therapy designed to address the negative symptoms of schizophrenia, such as social withdrawal, reduced motivation and diminished emotional expression.